![The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer | SpringerLink The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11255-019-02261-8/MediaObjects/11255_2019_2261_Fig1_HTML.png)
The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer | SpringerLink
![PSA Screening — Dr James Thompson is an experienced Urological Surgeon specialising in robotic surgery for prostate and bladder cancer PSA Screening — Dr James Thompson is an experienced Urological Surgeon specialising in robotic surgery for prostate and bladder cancer](https://images.squarespace-cdn.com/content/v1/5d09944f1c172000010bf8dd/1568691444906-3U5KAS2EWG63K9E1WV0V/Untitled-6-01.png)
PSA Screening — Dr James Thompson is an experienced Urological Surgeon specialising in robotic surgery for prostate and bladder cancer
![A predictive model for prostate cancer incorporating PSA molecular forms and age | Scientific Reports A predictive model for prostate cancer incorporating PSA molecular forms and age | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-58836-4/MediaObjects/41598_2020_58836_Fig1_HTML.png)
A predictive model for prostate cancer incorporating PSA molecular forms and age | Scientific Reports
![SciELO - Brasil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection SciELO - Brasil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection](https://minio.scielo.br/documentstore/1677-6119/rZqzS6ngfHjyJxNWvHmW5qy/4966e23dbbb57e0e806f4c569f2439f76166ebb8.gif)
SciELO - Brasil - Prostatic specific antigen for prostate cancer detection Prostatic specific antigen for prostate cancer detection
![Frontiers | New Diagnostic Model for Clinically Significant Prostate Cancer in Biopsy-Naïve Men With PIRADS 3 Frontiers | New Diagnostic Model for Clinically Significant Prostate Cancer in Biopsy-Naïve Men With PIRADS 3](https://www.frontiersin.org/files/Articles/908956/fonc-12-908956-HTML/image_m/fonc-12-908956-g001.jpg)
Frontiers | New Diagnostic Model for Clinically Significant Prostate Cancer in Biopsy-Naïve Men With PIRADS 3
Mobile Application-Based Seoul National University Prostate Cancer Risk Calculator: Development, Validation, and Comparative Analysis with Two Western Risk Calculators in Korean Men | PLOS ONE
![Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate Agnihotri S, Mittal RD, Ahmad S, Mandhani A - Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate Agnihotri S, Mittal RD, Ahmad S, Mandhani A -](https://www.indianjurol.com/articles/2014/30/1/images/IndianJUrol_2014_30_1_28_124202_t3.jpg)
Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate Agnihotri S, Mittal RD, Ahmad S, Mandhani A -
Sunnybrook Health Sciences Centre ~ News & Media ~ Prostate Cancer Risk Online Tool Supports More Dialogue
![Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening | Scientific Reports Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-77668-w/MediaObjects/41598_2020_77668_Fig1_HTML.png)
Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening | Scientific Reports
![A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-43427-9/MediaObjects/41598_2019_43427_Fig1_HTML.png)
A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor | Scientific Reports
![Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels | Prostate Cancer and Prostatic Diseases Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.pcan.4500957/MediaObjects/41391_2007_Article_BF4500957_Fig1_HTML.jpg)
Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels | Prostate Cancer and Prostatic Diseases
![Table 3 from Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less | Semantic Scholar Table 3 from Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5bbcdc5c6576e0425042645222a1a433570d3e04/3-Table3-1.png)
Table 3 from Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less | Semantic Scholar
![MP56-09 A RISK CALCULATOR INCORPORATING MRI-GUIDED BIOPSY DATA TO PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER | Journal of Urology MP56-09 A RISK CALCULATOR INCORPORATING MRI-GUIDED BIOPSY DATA TO PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER | Journal of Urology](https://www.auajournals.org/cms/asset/c14cc58a-dba4-426f-9e72-f09b0e565ced/ju.0000000000000925.09t1.gif)